Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma

被引：0
|
作者：
Shah, Jatin J. [1 ]
Harvey, R. Donald [2 ]
O'Connor, Owen A. [3 ]
Jakubowiak, Andrzej J. [4 ]
Smith, Mitchell R. [5 ]
Orlowski, Robert Z. [1 ]
Mulligan, George J. [6 ]
Smith, Peter G. [7 ]
Pickard, Michael D. [8 ]
Dezube, Bruce J. [9 ]
Lonial, Sagar [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Emory Univ, Winship Cancer Inst, Atlanta, GA 30322 USA
[3] NYU Langone Med Ctr, Dept Med, NYU Canc Inst, New York, NY USA
[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Lymphoma Serv, Philadelphia, PA 19111 USA
[6] Millennium Pharmaceut Inc, Mol Med, Cambridge, MA USA
[7] Millennium Pharmaceut Inc, Discovery, Cambridge, MA USA
[8] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
[9] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1155 / 1155
页数：1
相关论文
共 50 条
  • [21] Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells
    Wang, Yanchun
    Luo, Zhongguang
    Pan, Yongfu
    Wang, Weige
    Zhou, Xiaoyan
    Jeong, Lak Shin
    Chu, Yiwei
    Liu, Jie
    Jia, Lijun
    CANCER BIOLOGY & THERAPY, 2015, 16 (03) : 420 - 429
  • [22] Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Bixby, Dale L.
    Altman, Jessica K.
    Maris, Michael
    Hua, Zhaowei
    Blakemore, Stephen J.
    Faessel, Helene
    Sedarati, Farhad
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 534 - 543
  • [23] MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study
    Assouline, Sarit
    Chang, Julie
    Rifkin, Robert
    Hui, Ai-Min
    Berg, Deborah
    Gupta, Neeraj
    Xi, Yingmei
    Di Bacco, Alessandra
    Martin, Peter
    BLOOD, 2011, 118 (21) : 1148 - 1148
  • [24] The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Smith, Peter G.
    Pickard, Michael D.
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BLOOD, 2010, 116 (21) : 288 - 288
  • [25] Antitumor activity of MLN4924, a novel small molecule inhibitor of Nedd8-activating enzyme, in pre-clinical models of lymphoma
    Smith, Peter G.
    Milhollen, Michael
    Traore, Tary
    Zhang, Julie
    Berger, Allison
    Yu, Jie
    Garnsey, James
    Langston, Steve
    Soucy, Teresa
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3602S - 3602S
  • [26] Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, MLN4924, Demonstrates Activity Against Primary AML Blast, Progenitor and Stem Cell Populations
    Sen, Siddhartha
    De Leon, Jeanne P.
    Smith, Peter G.
    Roboz, Gail J.
    Guzman, Monica L.
    BLOOD, 2011, 118 (21) : 615 - 615
  • [27] Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
    Assouline, S. E.
    Chang, J.
    Cheson, B. D.
    Rifkin, R.
    Hamburg, S.
    Reyes, R.
    Hui, A-M
    Yu, J.
    Gupta, N.
    Di Bacco, A.
    Shou, Y.
    Martin, P.
    BLOOD CANCER JOURNAL, 2014, 4 : e251 - e251
  • [28] Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
    S E Assouline
    J Chang
    B D Cheson
    R Rifkin
    S Hamburg
    R Reyes
    A-M Hui
    J Yu
    N Gupta
    A Di Bacco
    Y Shou
    P Martin
    Blood Cancer Journal, 2014, 4 : e251 - e251
  • [29] ONCE-WEEKLY MLN9708, AN INVESTIGATIONAL PROTEASOME INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA: RESULTS OF A PHASE 1 DOSE-ESCALATION STUDY
    Assouline, S.
    Chang, J.
    Rifkin, R.
    Hui, A-M
    Gupta, N.
    Yu, J.
    Di Bacco, A.
    Shou, Y.
    Martin, P.
    HAEMATOLOGICA, 2012, 97 : 434 - 434
  • [30] Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
    Assouline, Sarit
    Chang, Julie E.
    Cheson, Bruce D.
    Rifkin, Robert
    Hamburg, Solomon
    Reyes, Ruben
    Hui, Ai-Min
    Yu, Jiang
    Gupta, Neeraj
    Di Bacco, Alessandra
    Shou, Yaping
    Martin, Peter
    BLOOD, 2012, 120 (21)
12345